Page **1** of **30** 

1 The role of plasmapheresis in snake envenoming: a systematic review 2 Hari Prasad<sup>1</sup>¶, Nidhi Kaeley <sup>2\*¶</sup>, Jewel Rani Jose<sup>3</sup>¶, Ajun U N<sup>4</sup>&, Takshak Shankar<sup>5</sup>&, Ajmal Salam<sup>6</sup>&, Krishna 3 Shukla<sup>7&</sup> 4 1. Senior Resident, Department of Emergency Medicine, All India Institute of Medical Sciences, New 5 Delhi, India, hariprasad007007007@gmail.com 6 2. Head of Department, Department of Emergency Medicine, All India Institute of Medical Sciences, 7 Rishikesh, India, nidhi.em@aiimsrishikesh.edu.in 8 Junior Resident, Department of Emergency Medicine, All India Institute of Medical Sciences, Rishikesh, 9 India, jewka4229@gmail.com 10 Senior Research Officer, Department of Psychiatry, National Institute of Mental Health and Neuro 11 Sciences, Bengaluru, India, ajun563@gmail.com 12 5. Senior Resident, Department of Emergency Medicine, All India Institute of Medical Sciences, Rishikesh, 13 India, takshak.shankar@gmx.com Senior Resident, Department of Paediatrics, Aster DM Wayanad Institute of Medical Sciences, Wayanad, 14 15 India, ajmalwims@gmail.com 16 7. DrNB Trainee, Department of Critical Care Medicine, Medanta, The Medicity, Gurgaon, India, 17 krishna.shukla03@gmail.com 18 Correspondence: nidhi.em@aiimsrishikesh.edu.in 19 20 21 22 23 24 25 26

Page 2 of 30

**Background-** Envenoming from numerous sources, such as snakes, scorpions, and spiders, is a major health issue across the world, resulting in millions of cases and tens of thousands of deaths annually. Venom induced symptoms ranges from systemic reactions like nausea and vomiting to localised pain and swelling. One major risk is the development of venom induced consumption coagulopathy (VICC), which might result in significant consequences. Plasmapheresis is being investigated as a possible therapy for severe envenoming. **Objectives**-We aim to assess the effectiveness and potential advantages of plasmapheresis in snakebite cases, focusing on clinical results. We seek to find if plasmapheresis improves neurological, renal, and hematological dysfunction and impacts secondary outcomes, including patient discharge rates, morbidity, mortality, duration of hospital stay, and the number of plasmapheresis sessions required. Methods- Following PRISMA guidelines, we conducted a systematic search of articles published between 1980 and July 2023 across multiple databases. MeSH terms related to snakebite and plasmapheresis were applied without publication or language type restrictions. Inclusion criteria considered case reports, cross-sectional studies, or case series featuring plasmapheresis in snakebite management. Inclusions were participants aged 18 years or older with confirmed or suspected snakebites, meeting plasmapheresis indications. Exclusions included participants under 18 years, studies reporting only in vitro data, review articles, and redundant reporting. The emphasis was on Emergency Departments or Intensive Care Units. Results- In a review of 147 cases (1980 to July 2023), the most common snake was the hump-nosed viper (Hypnale hypnale). Renal, neurological, and hematological dysfunctions improved after plasmapheresis. The mean plasmapheresis sessions were 2.1, and the average hospital stay was 13.13 days. Conclusion- Once the data has been analyzed, the result emphasizes the clinical importance of plasmapheresis in snakebite envenoming. It helps decision-making when standard therapies are insufficient or ineffective, potentially saving lives. Keywords- plasmapheresis, snakebite, snake bite, snakebite envenoming, therapeutic plasma exchange

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

**Abstract** 

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

Page **3** of **30** 

**Author Summary** Snakebites pose a significant global health threat, causing numerous deaths and serious injuries annually. While antivenom is the primary treatment, it's not always effective or available. This study explores an alternative treatment called plasmapheresis, a method that filters harmful substances from the blood. We reviewed 147 cases of snake envenoming treated with plasmapheresis between 1980 and 2023. Our findings show that plasmapheresis can improve various complications caused by snake venom, including kidney problems, nerve damage, and blood disorders. On average, patients received about two plasmapheresis treatments and stayed in the hospital for around 13 days. The study suggests that plasmapheresis could be a valuable option when standard treatments aren't working well enough. It might help save lives in severe cases of snake envenoming. While more research is needed, this review provides important insights for doctors treating snakebite victims, especially in areas where snakebites are common and resources are limited. **Background** Envenoming causes significant morbidity and mortality; the most common causes are snakes, scorpions, spiders, bugs, and unidentified bites [1]. According to the World Health Organisation (WHO), there are 2.7 million snake bites globally each year, resulting in 81,000 to 138,000 deaths [2]. Snakebite is classified as a category A Neglected Tropical Disease (NTD) by the WHO [3]. Each year, there are over 81,000 occurrences of snakebite envenoming in India, resulting in 11,000 fatalities [4]. Indian Cobra (Naja Naja), Russell's Viper (Daboia russelii), and Krait (Bungarus caeruleus) are among the most harmful and venomous snakes. Examples of local symptoms include painful regional lymphadenopathy, edema, and discomfort at the bite site. Nausea, vomiting, headaches, diaphoresis, stomach discomfort, and diarrhoea are examples of non-specific systemic symptoms. Toxin syndromes such as neurotoxicity, myotoxicity, and VICC can result from systemic envenoming [5]. Some elapid envenomings cause hemostatic and cardiovascular consequences [6]. Acute kidney injury (AKI), VICC, and tissue destruction are all caused by metalloproteinases, phospholipase A2, and snake lectins, in hematotoxic venom. The major toxin-mediated coagulopathy brought on by a hemotoxic snakebite is VICC, which is then followed by venom-induced Thrombotic Microangiopathy (TMA) and Diffuse

Page 4 of 30

Alveolar Hemorrhage (DAH) [7,8]. Russell's viper (Daboia russelii) envenoming causes a specific condition known as Capillary Leak Syndrome (CLS) [9]. Drowsiness, visual abnormalities, and respiratory failure are neurotoxicity signs [6]. Rarely, a snakebite can result in Guillain-Barre Syndrome (GBS) and Insulin Autoimmune Syndrome (IAS), which is treatable with plasmapheresis. For AKI, hemotoxic consequences, CLS, hemodialysis, and antisnake venom are used. But for many, plasmapheresis is a last-ditch option. Plasma exchange is an alternate method for removing venom toxins that are difficult to remove using dialysis or hemoperfusion. Venom toxins can be effectively removed from the blood by plasma exchange but not from other fluid compartments. Plasma exchange may help to reduce venom toxins in the blood compartment and may even cause venom toxins to be redistributed and removed from the extravascular region. Kornalik reported the first instance of plasma exchange being utilized to treat snake bite envenoming in 1990. Rasulov and Berdymuradov reported using plasma exchange in 1994 to treat three of 24 patients who had been bitten by snakes and become envenomed. Zengin et al. found plasmapheresis to be an effective intervention in a retrospective study of 37 snakebite patients with complications not resolving with antivenom administration [10]. Herein, we aim to conduct a systematic review to assess the effectiveness of plasmapheresis in snakebite cases and the situations under which it may be beneficial.

### Methods

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

# Search strategy

PROSPERO (ID: CRD42023459261) was used to register the study protocol. Prior to the start of the systematic review, a protocol was created using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). A comprehensive search approach for articles from 1980 to July 2023 was carried out. PubMed, Embase via Elsevier, MEDLINE via Ovid, The Cochrane Library for Cochrane Reviews, Scopus, Web of Science, and Google Scholar were searched with the MeSH terms 'bite' or 'snakebite' or 'envenomation' or 'snakebite envenoming' and 'plasmapheresis' or 'therapeutic plasma exchange.' Additionally, we contacted the research authors for any missing data, manually checked the reference lists of the included studies, and utilised a database's similar articles function.

## Study selection and screening

HP, NK, and JJ independently screened search results for eligibility. For articles eligible after screening, full texts were retrieved by HP, NK, and JJ, which HP, JJ, NK, AU, TS, AS and KS reviewed. HP and JJ screen the citation search. Discrepancies were resolved by consensus. The selection process was done as in Fig. 1 [11].




Fig. 1- PRISMA above shows the flow of patients.

### **Eligibility Criteria**

This review aimed to find, assess, and synthesize all cross-sectional studies, case reports, or case series that used plasmapheresis for snakebite along with conventional Anti Snake Venom (ASV), atropine-neostigmine, calcium gluconate or hemodialysis. Only human cases aged more than 18 years, suspected or confirmed snakebites or those who fulfill indications of plasmapheresis were included in the review. We excluded Human cases under 18 years, studies reporting in vitro data only, review articles, or those with complete reporting overlap. The study was set in an Emergency Department or Intensive Care Unit as patients with complications mostly come here.

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

Page 6 of 30

**Data extraction** HP and JJ were the authors who extracted the data. Each included study provided the following data regarding study characteristics and outcomes: • Study types: observational studies • The study's methods included: Authors of the study, year, and study design • The intervention(s) of interest: kind, frequency, and comparator(s) used: normal care • Age, gender, and the outcomes listed above were characteristics of the participants' studies. Assessment of the Risk of Bias The risk of bias for each research was independently assessed by five review authors (NK, AN, TS, HP, JJ, AS and KS) using the Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid-Based Med. 2018;23(2): 60–3 [12]. Outcome The study's primary outcomes were 'improvement in renal dysfunction' defined as patients becoming KDIGO 1 at discharge, 'improvement in neurological dysfunction' defined as Guillain Barre Syndrome disability score 0-2 at discharge, or 'improvement in hematological dysfunction' described as hemoglobin and platelets returning to age-appropriate normal limits without schistocytes following plasmapheresis done for snakebite. The secondary outcomes were discharge or death, morbidity (KDIGO 2 or3, Guillain Barre Syndrome disability score 3-5, no return to age-appropriate limits for hemoglobin and platelets), hospital stay duration, and number of plasmapheresis. This helps to determine the role of plasmapheresis and its effectiveness in the snakebite. **Analysis** The mean and standard deviation for normal distributions, the median (interquartile range) for non-normal distributions of numerical variables, and percentages and proportions for categorical variables were the ways in which descriptive statistics were stated. The data was analysed using SPSS 23.0.

### Results

140

141

142

143

144

145

146

147

148

149

150

151

152

153

This systematic review includes 147 patients from 40 studies carried out between 1980 and July 2023. The population's average age was  $49.9 \pm 14$  years, with 59.9% of patients being male.

Main results: Regarding the types of snake bites, 77 cases involved unidentified snake species, while the humpnosed viper (Hypnale hypnale, one of which is Hypnale zara) accounted for most known snakebites (42). This was followed by eight each for Russell's viper (Daboia russelli) and saw-scaled viper (five Echis carinatus, one Echis pyramidum, one Echis coloratus, one Echis sochureki), three pit vipers (two Bothrops asper, one Crotalus cerastes), and other viper species (Proatheris superciliaris, Cerastes cerastes) accounting for two. Additionally, there were three krait bites (one Bungarus caeruleus, one Bungarus multicinctus, one Bungarus candidus), one sea snake bite (Hydrophis platurus), one Australian brown snake bite (Pseudonaja nuchalis), one taipan bite (Oxyuranus scutellatus), and one Colubridae snake bite (Notechis scutatus).

A summary table showing study included, type of snake, indication for plasmapheresis and geographical location of snakebite are shown in Tabe 1.

# Table 1: Summary Table

Sl.No	Author	Study	Snake	Indication	Geographical
					Location
1.	Yildirim et al. [13]	Retrospective	N/A	VICC	Turkey
		descriptive			
		study			
2.	Arora et al. [14]	Case report	Daboia russelii	TMA	India
3.	Mohan et al. [15]	Case report	Daboia russelii	TMA	India
4.	Zengin et al. [10]	Retrospective	N/A	VICC	Turkey
		observational			
		study			
5.	Berber et al. [16]	Observational	N/A	VICC	Turkey
		study			

Page **8** of **30** 

6.	Dineshkumar et	Case report	Daboia russelii	TMA	India
	al. [17]				
7.	Erkurt et al. [18]	Retrospective	N/A	VICC	Turkey
		observational			
		study			
8.	Rathnayaka et al.	Prospective	Hypnale	TMA	Srilanka
	[19]	observational	hypnale		
		study			
9.	Isbister et al. [20]	prospective	Pseudonaja	TMA	Australia
		observational	nuchalis		
		study			
10.	Rahmani et al.	Case series	Echis coloratus	TMA	Israel
	[21]				
11.	Obeidat et al. [22]	Case Report	Echis carinatus	TMA	Jordan
12.	Keyler et al. [23]	Case Report	Proatheris	TMA	USA
			superciliaris		
13.	Kornalík et al.	Case Report	Bothrops asper	VICC	Czechoslovakia.
	[24]				
14.	Valenta et al. [25]	Case Report	Echis	TMA	Czech Republic
			pyramidum		
15.	Sampley et al.	Case Report	N/A	DAH	India
	[26]				
16.	Grace et al. [27]	Case Report	N/A	CLS	India
17.	Hameed et al. [28]	Case Report	Hydrophis	GBS	Pakistan
			platurus		
18.	Cobcroft et al.	Case Report	Oxyuranus	TMA	Australia
	[29]		scutellatus		
19.	Chuang et al. [30]	Case Report	Bungarus	GBS	Taiwan
			multicinctus		

Page **9** of **30** 

20.	Akhilesh Kumar	Case Report	Echis sochureki	DAH	India
	et al. [8]				
21.	Withana et al. [31]	Case Report	Hypnale	TMA	Srilanka
			hypnale		
22.	Mitrakrishnan et	Case Report	Hypnale	TMA	Srilanka
	al. [32]		hypnale		
23.	Rathnayaka et al.	Case Series	Daboia russelii	TMA	Srilanka
	[33]				
24.	Srivastava et al.	Case Report	N/A	GBS	India
	[34]				
25.	Reddy et al. [35]	Case Report	Daboia russelii	TMA	India
26.	Cañas et al. [36]	Case Report	Bothrops asper	TMA	Colombia
27.	Rathnayaka et al.	Case report	Hypnale zara	TMA	Srilanka
	[37]				
28.	Godavari et al.	Case Report	N/A	TMA	India
	[38]				
29.	Murthy et al. [39]	Case Report	N/A	TMA	India
30.	Wijewickrama et	Prospective	Hypnale	TMA	Srilanka
	al. [40]	observational	hypnale		
		study			
31.	Janarthanam et al.	Case Report	Crotalus	GBS	India
	[41]		cerastes		
32.	Senthilkumaran et	Case Report	Bungarus	IAS	India
	al. [42]		caeruleus		
33.	Priyankara et al.	Case Report	Daboia russelii	TMA	Srilanka
	[43]				
34.	Laothong et al.	Case Series	Bungarus	GBS	Thailand
	[44]		candidus		

Page **10** of **30** 

35.	Herath et al. [45]	case series	Hypnale	TMA	Srilanka
			hypnale		
36.	Bava et al. [46]	Case series	Echis carinatus	DAH, VICC,	India
				TMA	
37.	Elmoqaddem et	Case report	Cerastes	VICC	Morocco
	al. [47]		cerastes		
38.	Casamento et al.	Case Series	Notechis	TMA	Australia
	[48]		scutatus		

CLS, Capillary Leak Syndrome; DAH, Diffuse Alveolar Hemorrhage; GBS, Guillain-Barre Syndrome; IAS, Insulin Autoimmune Syndrome; TMA, Thrombotic Microangiopathy; USA, United States of America; VICC, venom-induced consumption coagulopathy

154

155

156

157

158

159

Among the indications for plasmapheresis, the majority (51%) was performed for VICC, while 42.2% of cases were for TMA and 3.4% for GBS. Three cases involved DAH, and one each involved CLS and IAS, all of which underwent plasmapheresis.

Sl.No	Author	Number	Age or	Sex (Number	Renal	Neurological	Blood
		of	Range	of	dysfunction	dysfunction	dysfunction
		patients		Male/Female)	present or	present or	present or
		*			not. If yes	not. If yes	not. If yes
					improved or	improved or	improved or
					deteriorated	deteriorated	deteriorated
					following	following	following
					TPE	TPE	TPE
1.	Yildirim et al.	13	21-75	9/4	-	-	Yes,
	[13]						Improved
2.	Arora et al. [14]	1	44	1/-	Yes,	-	Yes,
					Improved		Improved
3.	Mohan et al.	1	70	-/1	Yes,	-	Yes,
	[15]				Improved		Improved

Page **11** of **30** 

4.	Zengin et al.	33	20-79	19/14	Yes,	-	Yes,
	[10]				Improved		Improved
5.	Berber et al.	20	49.55	17/3	Yes, 19	-	Yes, 19
	[16]				improved 1		improved 1
					Death		Death
6.	Dineshkumar et	1	56	1/-	Yes/ Not	-	Yes/
	al. [17]				improved-		Improved
					ESRD		
7.	Erkurt et al. [18]	5	21-80	1/4	Yes,		Yes,
					Improved		Improved
8.	Rathnayaka et	21	29-70	14/7	Yes/ 16	-	Yes/ 20
	al. [19]				improved 5		improved 1
					Not		Not
					improved (1		improved-
					Death, 4		Death
					ESRD)		
9.	Isbister et al.	1	42	1/-	Yes,	-	Yes,
	[20]				Improved		Improved
10.	Rahmani et al.	2	39,70	2/-	Yes,	-	Yes,
	[21]				Improved		Improved
11.	Obeidat et al.	1	25	1/-	Yes,	-	Yes,
	[22]				Improved		Improved
12.	Keyler et al.	1	27	1/-	Yes,	-	Yes,
	[23]				Improved		Improved
13.	Kornalík et al.	1	60	1/-	-	-	Yes,
	[24]						Improved
14.	Valenta et al.	1	41	1/-	Yes,	-	Yes,
	[25]				Improved		Improved
15.	Sampley et al.	1	36	1/-	Yes,	-	Yes,
	[26] €				Improved		Improved

Page **12** of **30** 

16.	Grace et al. [27]	1	28	1/-	Yes,	-	Yes,
	3				Improved		Improved
17.	Hameed et al.	1	21	1/-	-	Yes/ Not	-
	[28]					improved-	
						Neurodeficit	
18.	Cobcroft et al.	1	33	1/-	Yes/ Not	-	Yes/ Not
	[29]				improved-		improved-
					Death		Death
19.	Chuang et al.	1	36	1/-	-	Yes/	-
	[30]					Improved	
20.	Akhilesh	1	40	1/-	-	-	Yes,
	Kumar et al. [8]						Improved
	Ω						
21.	Withana et al.	1	55	-/1	Yes,	-	Yes,
	[31]				Improved		Improved
22.	Mitrakrishnan	1	70	1/-	Yes,	-	Yes,
	et al. [32]				Improved		Improved
23.	Rathnayaka et	1	66	-/1	Yes, Not	-	Yes,
	al. [33]				Improved-		Improved
					ESRD		
24.	Srivastava et al.	1	40	1/-	-	Yes,	-
	[34]					Improved	
25.	Reddy et al.	1	55	-/1	Yes,	-	Yes,
	[35]				Improved		Improved
26.	Cañas et al. [36]	1	57	1/-	Yes,	-	Yes,
					Improved		Improved
27.	Rathnayaka et	3	55-74	2/1	Yes,	-	Yes,
	al. [37]				Improved		Improved
28.	Godavari et al.	2	30,49	1/1	Yes,	-	Yes,
	[38]				Improved		Improved

Page **13** of **30** 

29.	Murthy et al.	1	51	1/-	Yes,	-	Yes,
	[39]				Improved		Improved
30.	Wijewickrama	9	39-59	3/6	Yes,	-	Yes,
	et al. [40]				Improved		Improved
31.	Janarthanam et	1	29	-/1	-	Yes,	-
	al. [41]					Improved	
32.	Senthilkumaran	1	54	-/1	-	-	-
	et al. [42] #						
33.	Priyankara et al.	1	70	-/1	Yes,	-	Yes,
	[43]				Improved		Improved
34.	Laothong et al.	1	35	1/-	-	Yes,	-
	[44]					Improved \$	
35.	Herath et al.	7	44-76	3/4	Yes/ 3	-	Yes, 5
	[45]				Improved 4		Improved, 2
					Not		Not
					improved (2		improved-
					Death, 2		Death
					ESRD)		
36.	Bava et al. [46]	3	40-50	2/1	Yes, 2	-	Yes, 2
	¥				Improved		Improved
37.	Elmoqaddem et	1	43	1/-	Yes,	-	-
	al. [47]				Improved		
38.	Casamento et al.	1	55	-/1	Yes,	-	Yes,
	[48]				Improved		Improved
	1	1	1	1	1	i .	1

#### 160 ESRD End Stage Renal Disease

161

- \* Number of patients with snakebite as per inclusion criteria of the review
- #- Patient with Insulin Autoimmune syndrome post snakebite improved following TPE 162

Page **14** of **30** 

163 € This patient with DAH post snakebite had concomitant renal and blood dysfunction too all 3 improved following 164 TPE 165 3 This patient with CLS post snakebite had concomitant renal and blood dysfunction too all 3 improved following 166 TPE 167  $\Omega$  This patient with DAH post snakebite had concomitant blood dysfunction both of which improved following 168 TPE 169 \$ Improved but have persistent autonomic dysfunction 170 ¥ Patient with DAH post snakebite improved following TPE 171 Of the 124 patients who developed renal dysfunction, 112 showed improvement after plasmapheresis. Five of the 172 173 eight patients who developed neurological dysfunction showed improvement after plasmapheresis. Of the 136 patients who developed hematological derangements, 124 improved after plasmapheresis. Furthermore, one 174 175 patient with IAS who developed autonomic dysfunction also improved after plasmapheresis. 176 From the available data, 90.5% of patients were discharged from the hospital, while nine patients succumbed to 177 death. Among the patients, 86.4% did not develop residual clinical effects on discharge (no morbidity), 7.5% 178 developed end-stage renal disease, two developed residual limb weakness, and one developed autoimmune 179 dysfunction. Relation of indication for plasmapheresis and duration of hospital stay is shown in Fig. 2. 180 181 Fig. 2: Mean duration of hospital stay and indications of plasmapheresis 182




Fig. 2: Bar diagram showing mean duration of hospital stay with plasmapheresis indications

CLS, Capillary Leak Syndrome; DAH, Diffuse Alveolar Hemorrhage; GBS, Guillain-Barre Syndrome; IAS, Insulin Autoimmune Syndrome; TMA, Thrombotic Microangiopathy; VICC, venom-induced consumption coagulopathy

The duration of hospital stay showed high variability, ranging from 1 to 65 days, with a mean of 13.1 days. The number of plasmapheresis sessions ranged from 1 to 14, with a median of 2 and an interquartile range (IQR) of (1,4).

## Discussion

Snakebites are an occupational danger, with the majority of bites occurring on farms when working barefoot or wandering through the fields at night. The four families of venomous snakes are the Elapidae, Viperidae, Hydrophidae, and Colubridae. Elapid venom's most prevalent clinical effects are neurotoxic, whereas viper venom causes vascular toxicity and nephropathy, and Hydrophiinae or sea snake venom is myotoxic [49].

AKI is a common complication of snakebite and a significant cause of death and morbidity. 75% of instances of AKI in this situation are caused by acute tubular necrosis (ATN), while 5–15% of cases are caused by acute interstitial nephritis (AIN) [38]. The prevalence of AKI following Russell's viper (*Daboia russelii*) and *Echis carinatus* bites ranges from 13 to 32%. Pathogenesis of AKI in snake envenoming involves hemolysis, rhabdomyolysis, DIC, sepsis, hemodynamic abnormalities, and cell damage caused by the production of proinflammatory cytokines and vasoactive mediators [17,38].

### Venom induced consumption coagulopathy (VICC)

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226 227

228

229

230

231

232

Page **16** of **30** 

The hemotoxic venom activates coagulation pathways leading to VICC without thrombocytopenia and is characterized by severe bleeding without visible fibrin deposition, microvascular thrombosis, or end-organ failure, which results from snake toxins activating the coagulation pathway. This results in a prolonged prothrombin time, increased fibrinogen consumption, and elevated D-dimer levels, all overlapping with DIC. TMA appears in a subset of individuals with or without VICC whom a snake bite has envenoming. While the coagulopathy in VICC resolves rapidly, the triad of TMA (AKI, thrombocytopenia, and microangiopathic hemolytic anemia) persists for longer. Most cases of TMA following snake envenoming have been documented in Sri Lanka and Australia; very few cases have been reported in India. The proposed mechanism is that venom or its vascular endothelial toxins may function as factors related to VEGF or von Willebrand factor (vWF) activators and cause endothelium damage to initiate TMA. The role of ADAMTS-13, a VWF-cleaving protease, in snake bites requires more investigation [14,17]. The symptoms of TMA often begin 1-3 days after the bite and last longer than those of VICC, which typically resolves after 12-24 h of antivenom infusion. According to Bull et al., either the presence of intravascular fibrin or endothelial injury may predispose to fibrin deposition [50]. These data show that TMA may not always be the same as VICC. Certain species, including B. jararaca, induce TMA by up-regulating and activating the genes that produce inflammatory mediators such matrix metalloproteinase (MMP)-10, IL-8, VCAM-1, and E-selectin. Jararhagin, a hemorrhagic metalloproteinase discovered from B. jararaca venom, may cause a systemic proinflammatory response [51,52]. The ecarin enzyme converts prothrombin directly into meizothrombin and is primarily responsible for the pathophysiology of envenoming in members of the Echis genus. Disintegrins, including echistatin, ocellatin, and pyramidin, are other venom components that prevent platelet aggregation [53]. Hemorrhaging-like substances exacerbate prothrombotic activation and the production of fibrin deposits and lead to afibrinogenemia [25]. TPE for VICC was done in 51.1% of the study's subjects, with 98.6% having their blood dysfunction improved. Thrombotic Micro Angiopathy (TMA) TMA is a pathological diagnosis and is associated with acute kidney injury (AKI), Microangiopathic Hemolytic Anemia (MAHA) and thrombocytopenia. Thrombotic thrombocytopaenic purpura (TTP) and haemolytic uraemic syndrome (HUS) are the prototype diseases associated with TMA. The first is thrombotic thrombocytopenic purpura (TTP), which was discovered in 1925 in a 16-year-old female patient by Eli Moschcowitz. The second

condition is hemolytic uremic syndrome (HUS), which was discovered by Gasser in 1955 in five newborns who

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

had renal failure, thrombocytopenia, and hemolytic anaemia as a result of a diarrheal sickness [54,55]. Bite-related HUS or HUS-like alterations in Western Australia have been linked to gwadar (*Demansia nuchalis nuchalis*), dugite (Demansia nuchalis affinis), and Russell's viper (Daboia russelii) bites in India. The difference between HUS and TTP is a little arbitrary because there is much overlap between the two, and it would be preferable to think of them as a continuum of a related disease process [29]. TMA is not included in the categories of complement factor dysregulation or ADAMTS 13 deficiency. The primary cause of TMA pathogenesis, according to the study, is endothelial cell damage or dysfunction, which exposes thrombogenic components to coagulation factors and platelets. Endothelial damage occurs as a result of uncontrolled inflammation and/or genetic or acquired abnormalities of complement or hemostasis mediators, as shown in TMA. TPE may be considered as a therapy option for such people if TMA is shown to be the consequence of snake envenoming [15]. TPE for TMA was done in 42.2 % of the study's subjects, with 77.76 % having their renal dysfunction improved and 92.5% have their blood dysfunction improved. Guillain Barre Syndrome (GBS) The first instance of GBS associated with a snakebite was reported by Chuang et al. in 1996. Four weeks after being bitten by a Bungarus multicinctus, sensorimotor axonal-type polyneuropathy was identified by EMG/NCS. After therapy (plasmapheresis and 500 mg/day of methylprednisolone for five days), the patient's condition improved [30]. In 2010, Srivastava et al. reported that EMG/NCS revealed motor and sensory neuropathy five weeks after the bite, indicating demyelination with subsequent axonal degradation. Plasmapheresis aided the patient's recovery [34]. Neil et al. (2011) described a patient who experienced paraesthesia and quadriparesis 12 days after being bitten by a Vipera aspis snake. The researchers discovered molecular similarity between venom proteins and neuronal GM2 gangliosides, hypothesising an immunological explanation rather than direct venom toxicity for this relationship [28,56]. TPE for GBS was performed on 3.4% of the study's individuals, with four of them having neurological dysfunction improved and one having neurodeficit. One of those who improved had persisting autonomic dysfunction. Diffuse Alveolar Hemorrhage (DAH) DAH is a potentially fatal pulmonary complication in various conditions characterized by hypoxemia caused by alveolar infiltrates, which leads to alveolar hemorrhage and necessitates rapid treatment and lifesaving measures. DAH's causes can be immunological and non-immune. The pathophysiology includes widespread alveolar destruction, alveolar hemorrhage, and antibody-mediated pulmonary capillaritis. Direct venom action

Page **18** of **30** 

and/or an insult mediated by an antibody might account for the delayed DAH by causing widespread alveolar injury. Sampley et al. described DAH in viper envenoming during the first week, with a normal coagulation profile controlled with methylprednisolone and plasmapheresis. The effective use of plasmapheresis and methylprednisolone in DAH on day three following a hump-nosed pit viper (Hypnale hypnale) bite, including VICC and thrombotic microangiopathy, was described by Srirangan et al. Therefore, plasma exchange has a limited role in the treatment of snakebite despite evidence supporting its use in thrombotic microangiopathy [8.26]. TPE was performed on three individuals with DAH, two of whom had concurrent blood malfunction and one of whom had concurrent renal impairment. All of which improved after TPE.

## Capillary Leak Syndrome (CLS)

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

Dr. Bayard Clarkson discovered CLS, also known as Clarkson's illness, in 1960. Its defining features are hemoconcentration, hypotension, generalized edema, and hypoalbuminemia without albuminuria [57]. Capillary hyperpermeability and plasma extravasation are the essential mechanisms, CLS can develop as a primary (idiopathic) disorder or a complication of other illnesses. Snake venom contains toxins and enzymes that promote capillary permeability and cause plasma to escape from the intravascular region. The clinical appearance of CLS goes through three stages. First, a prodromal phase of irritation, myalgia, thirst, and syncope. Second, the capillary leakage phase is characterized by intravascular fluid extravasation. Third, complication phase-renal failure is a frequent complication [27]. There are no recognized diagnostic criteria, but with minor revisions, the Thomas and Kumar criteria can be used for diagnosis.

Treatment includes theophylline, leukotriene antagonists, terbutaline, plasmapheresis, corticosteroids, and intravenous immunoglobulin (IG), disease-modifying therapy medications. The outlook for CLS is still quite bad because there is no established treatment. We hypothesized that the patient's favorable result may have been influenced by early CLS detection, timely plasmapheresis implementation, and the use of fresh frozen plasma [58]. TPE was done for one patient with CLS post snakebite who had concomitant renal and blood dysfunction too all of which improved following treatment.

# Insulin Autoimmune Syndrome (IAS)

In the early 1970s, Hirata and colleagues described Insulin Autoimmune Syndrome (IAS). Postprandial hypoglycemia, increased insulin levels, and detectable insulin antibodies are all indications of IAS. These antibodies, most often IgG, are considered to bind to circulating insulin and inhibit its interaction with its receptor.

Page **19** of **30** 

There have been a few accounts of a snakebite-inducing IAS. Many biomolecules in snake venom have the potential to be antigenic. Common krait's (Bungarus caeruleus) venom may contain a compound with structural resemblance to endogenous insulin, leading to the production of antibodies against its epitope, or venoms could include substances that reduce disulfide and cause the production of monomers. The existence of the HLA-DRB1\*0406 allele has been linked to the onset of IAS. Dextrose infusions, corticosteroids, somatostatin, diazoxide, azathioprine, rituximab, metformin, dietary changes, and plasmapheresis have all been used to treat IAS. Plasmapheresis rapidly decreased the patient's autoantibody level and reversed their condition. Therefore, once the diagnosis has been made, particularly for individuals with krait (Bungarus caeruleus) envenoming, early usage of plasmapheresis will be beneficial [42]. One patient with Insulin Autoimmune syndrome post snakebite was there in study who improved following TPE

## **Plasmapheresis**

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

Plasma exchange is an alternate method for removing venom toxins that are difficult to remove using dialysis or hemoperfusion. Venom toxins can be effectively removed from the blood by plasma exchange but not from other fluid compartments. Plasma exchange may help to reduce venom toxins in the blood compartment and may even cause venom toxins to be redistributed and removed from the extravascular region. Kornalik reported the first instance of plasma exchange being utilized to treat snake bite envenoming in 1990. Rasulov and Berdymuradov reported using plasma exchange in 1994 to treat three of 24 patients who had been bitten by snakes and become envenomed. Zengin et al. found plasmapheresis to be an effective intervention in a retrospective study of 37 snakebite patients with complications not resolving with antivenom administration [10].

Plasmapheresis has been utilized to treat TMA caused by snake bites in the absence of antivenom. Plasma exchange therapy should be started before a laboratory test can definitively establish the diagnosis because of the substantial mortality risk associated with TTP. This lack of supporting evidence shows that plasma exchange has only a minor role in snakebite envenoming. Therapeutic plasma exchange for snakebite envenoming is classified as Category III, grade 2 C by the American Society for Apheresis (ASFA) (poor recommendation, low-quality or extremely low-quality evidence) [8].

According to the ASFA criteria, acquired TTP is a category I indication for TPE (grade 1A evidence). TPE has two advantages: it eliminates autoantibodies against ADAMTS13 and infuses donor plasma with exogenous

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

Page 20 of 30

ADAMTS13 enzyme. The ASFA classified (Shiga like Toxin-Producing E.coli) STEC-HUS as category IV. The argument for using TPE in aHUS is that when allogeneic donor plasma is utilized as the replacement fluid for the exchange; this treatment will eliminate the faulty complement proteins and autoantibodies against complement factor H (CFH). According to ASFA recommendations, TPE is a second-line treatment for patients with additional complement mutations (category II, grade 2C) and a first-line treatment for those who have anti-CFH autoantibodies (category I, grade 2C) [23,59]. Other indications for plasmapheresis include Guillain-Barré syndrome, ANCA-associated and Goodpasture glomerulonephritis, chronic demyelinating polyradiculoneuropathy, recurrent focal segmental glomerulosclerosis, hyperviscosity in monoclonal gammopathies, myasthenia gravis, and encephalitis (Category 1). Acute encephalomyelitis, cardiac and stem cell transplantation desensitisation, antiphospholipid syndrome, cryoglobulinemia, cardiomyopathy, Hashimoto encephalopathy, Lambert-Eaton syndrome, multiple sclerosis, and myeloma nephropathy (Category 2) are also included. Category 3 indications include acute liver failure, autoimmune hemolytic anaemia, burn shock, newborn lupus, chronic encephalitis, heparin-induced thrombocytopenia, pancreatitis, refractory thrombocytopenia, paraneoplastic syndromes, sepsis, and vasculitis. Systemic amyloidosis, dermatomyositis/polymyositis, and lupus nephritis are all classified under Category 4 [60]. Contraindications for therapeutic plasmapheresis include lack of central line access or large bore peripheral lines, hemodynamic instability or septicemia, a known allergy to fresh frozen plasma or replacement colloid/albumin, or heparin; relative contraindications include hypocalcemia and angiotensin-converting enzyme (ACE) inhibitor use within the previous 24 hours [61]. Complications of plasmapheresis are hypocalcemia or hypomagnesemia due to citrate anticoagulation, hypotension, flushing, nausea and vomitinghypothermia, fluid and electrolyte imbalances, transfusion reactions, thrombocytopenia and hypofibrinogenemia causing bleeding diatheses [62]. Plasmapheresis is an effective treatment for a variety of acute and chronic conditions. It may also be used to help prepare for operations and surgeries, as well as to support postoperative recovery and minimise respiration periods. In general, the risks and side effects are minor, with the most prevalent being brief hypotension and associated symptoms [63]. However, antivenom should be administered as soon as feasible, and plasma exchange should be considered as a supplemental therapy strategy for patients with severe envenoming, particularly in managing hematologic issues and limb preservation/salvage techniques. We believe that plasma exchange treatment is advantageous because it

Page **21** of **30** 

eliminates toxins and inflammatory mediators. If the envenoming from a snake bite cannot be adequately treated using standard methods, plasma exchange may be explored as part of the treatment [10]. So, we propose that plasmapheresis could be used in snakebites in complications such as VICC, TMA, GBS,

intervention in some circumstances. The effectiveness of plasma exchange in treating snake bite envenoming

DAH, CLS, and IAS. Given the rarity of presentation and lack of evidence, plasma exchange could be a lifesaving

should be clarified by conducting extensive randomized controlled trials.

## Limitations and strengths

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

We have included only case series, case reports, and cross-sectional studies as it is challenging to carry out a randomized controlled trial, case-control, or cohort study. The risk of bias was assessed by a nonconventional method using Murad et al. Comparative studies of hemodialysis versus plasmapheresis are required. Plasmapheresis is a costly procedure, and widespread availability is a concern.

The study's strength is that it is one of the first to analyze the role of plasmapheresis in snake bite and to list the indications when plasmapheresis may be used in snakebites.

## Conclusion

Snakebites are serious occupational hazards particularly affecting people in agricultural contexts. Various snake venoms have diverse toxicological profiles, including neurotoxicity, vascular toxicity, nephropathy, and myotoxicity. Acute kidney damage (AKI) is a common and serious complication of snakebite, usually caused by acute tubular necrosis. Hemotoxic venoms can cause coagulopathies, resulting in thrombotic microangiopathy (TMA), which is characterised by acute kidney injury, thrombocytopenia, and microangiopathic hemolytic anaemia. Plasma exchange (plasmapheresis) has emerged as a potential therapeutic option for snakebite complications such as TMA, Guillain-Barré syndrome, diffuse alveolar haemorrhage (DAH), and capillary leak syndrome (CLS). Despite limited evidence, plasmapheresis can be life-saving by removing toxins and inflammatory mediators from the circulation. It is especially useful when conventional therapies are insufficient. Randomised controlled trials are required for establishing the effectiveness of plasmapheresis in snakebite envenoming, however its use as an adjuvant treatment shows promise for improving patient outcomes in severe envenoming.

# Acknowledgements

Page 22 of 30

374 None 375 **Author Contributions** 376 NK had full access to all of the study's data and accepts responsibility for the data's integrity and the correctness 377 of the data analysis. As co-first authors, HP and JRJ contributed equally. 378 Corresponding author: NK 379 Concept and design: HP, NK, JRJ, AU, TS, AS, KS. 380 Acquisition, analysis, or interpretation of data: HP, JRJ, AU. 381 Drafting of the manuscript: HP, NK, JRJ, AS, AU, TS, KS 382 Critical revision of the manuscript for important intellectual content: HP, JRJ, NK, AS, KS, AU, TS 383 Statistical analysis: AU, HP, JRJ. 384 Administrative, technical, or material support: NK. 385 Supervision: HP, JRJ, NK, AS, KS, TS, AU 386 **Funding** 387 None. 388 Availability of data and materials 389 The datasets generated during and/or analysed during the current study are available from the corresponding 390 author on reasonable request. 391 **Declarations** 392 Ethics approval and consent to participate Not applicable. 393 394 **Consent for publication** 395 Not applicable

396

**Competing interests** 

The authors declare that they have no competing interests.

### **Author Information**

398

- 399 HP, Junior Resident, Department of Emergency Medicine, All India Institute of Medical Sciences, Rishikesh,
- 400 India, hariprasad007007007@gmail.com
- 401 NK, Head of Department, Department of Emergency Medicine, All India Institute of Medical Sciences, Rishikesh,
- 402 India, nidhi.em@aiimsrishikesh.edu.in
- JRJ, Junior Resident, Department of Emergency Medicine, All India Institute of Medical Sciences, Rishikesh,
- 404 India, jewka4229@gmail.com
- 405 AU, Junior Resident, Department of Community and Family Medicine, All India Institute of Medical Sciences,
- 406 Rishikesh, India, ajun563@gmail.com
- 407 TS, Senior Resident, Department of Emergency Medicine, All India Institute of Medical Sciences, Rishikesh,
- 408 India, takshak.shankar@gmx.com
- 409 AS, Junior Resident, Department of Paediatrics, All India Institute of Medical Sciences, Rishikesh, India,
- 410 <u>ajmalwims@gmail.com</u>
- 411 KS, MD, Senior Resident, Department of Emergency Medicine, All India Institute of Medical Sciences,
- 412 Rishikesh, India, krishna.shukla03@gmail.com

# 413 References

- 414 1. White J. Bites and stings from venomous animals: a global overview. Ther Drug Monit. 2000;22(1):65–8.
- 415 2. World Health Organization. Snakebite envenoming: a strategy for prevention and control [Internet].
- 416 Geneva: World Health Organization; 2019 [cited 2023 Aug 18]. 50 p. Available from:
- 417 https://apps.who.int/iris/handle/10665/324838
- 418 3. Lancet T. Snake-bite envenoming: a priority neglected tropical disease. The Lancet [Internet]. 2017 Jul
- 419 1 [cited 2022 Jul 23];390(10089):2. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-
- 420 6736(17)31751-8/fulltext
- 421 4. Kasturiratne A, Wickremasinghe AR, Silva N de, Gunawardena NK, Pathmeswaran A, Premaratna R, et
- 422 al. The Global Burden of Snakebite: A Literature Analysis and Modelling Based on Regional Estimates of

- Envenoming and Deaths. PLOS Med [Internet]. 2008 Nov 4 [cited 2023 Aug 18];5(11):e218. Available from:
- 424 https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0050218
- 425 5. Slagboom J, Kool J, Harrison RA, Casewell NR. Haemotoxic snake venoms: their functional activity,
- 426 impact on snakebite victims and pharmaceutical promise. Br J Haematol [Internet]. 2017 [cited 2023 Aug
- 427 18];177(6):947–59. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.14591
- 428 6. Schrire L, Muller GJ, Pantanowitz L. The diagnosis and treatment of envenomation in South Africa.
- 429 South African Institute for Medical Research; 1996.
- 430 7. Berling I, Isbister GK. Hematologic effects and complications of snake envenoming. Transfus Med Rev.
- 431 2015;29(2):82–9.
- 432 8. Kumar A, Gopalakrishnan M, Kuri HR, Bajpayee A, Kothari N, Garg MK. Case Report: Delayed Diffuse
- 433 Alveolar Hemorrhage in Echis sochureki Envenoming, Jodhpur, India. Am J Trop Med Hyg [Internet]. 2022 Jan
- 434 31 [cited 2023 Aug 18]; Available from: https://www.ajtmh.org/view/journals/tpmd/aop/article-10.4269-
- 435 ajtmh.21-1187/article-10.4269-ajtmh.21-1187.xml
- 436 9. Krishnadas T, Sasidharan PK. SNAKE BITES IN NORTH KERALA, DEMOGRAPHIC PROFILE
- 437 AND MEAURSES FOR PREVENTION. J Evol Med Dent Sci [Internet]. 2014 Jan 27 [cited 2023 Aug
- 438 18];3(4):990–9. Available from
- 439 https://go.gale.com/ps/i.do?p=AONE&sw=w&issn=22784748&v=2.1&it=r&id=GALE%7CA646117896&sid=
- 440 googleScholar&linkaccess=abs
- 441 10. Zengin S, Yilmaz M, Al B, Yildirim C, Yarbil P, Kilic H, et al. Plasma exchange as a complementary
- approach to snake bite treatment: an academic emergency department's experiences. Transfus Apher Sci Off J
- World Apher Assoc Off J Eur Soc Haemapheresis. 2013 Dec;49(3):494–8.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020
- statement: an updated guideline for reporting systematic reviews. BMJ [Internet]. 2021 Mar 29 [cited 2023 Oct
- 446 20];372:n71. Available from: https://www.bmj.com/content/372/bmj.n71
- 447 12. Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and
- case reports. BMJ Evid-Based Med. 2018 Apr;23(2):60–3.

- 449 13. Yildirim C, Bayraktaroğlu Z, Gunay N, Bozkurt S, Köse A, Yilmaz M. The use of therapeutic
- 450 plasmapheresis in the treatment of poisoned and snake bite victims: an academic emergency department's
- 451 experiences. J Clin Apheresis. 2006 Dec;21(4):219-23.
- 452 Arora P, Belwal S, Uniyal B, Saxena S. Plasmapheresis in a case of acute kidney injury with severe
- 453 hemolysis and thrombocytopenia due to hematotoxic (Russell's viper) snake bite. Saudi J Kidney Dis Transplant.
- 2020;31(1):276-80. 454
- 455 15. Mohan G, Guduri PR, Shastry S. Role of therapeutic plasma exchange in snake bite associated
- 456 thrombotic microangiopathy-A case report with review of literature. J Clin Apheresis. 2019 Aug;34(4):507–9.
- 457 16. Berber I, Korkmaz S, Sarici A, Erkurt MA, Kuku I, Kaya E, et al. Therapeutic plasma exchange for
- 458 envenomation: Is it reasonable? Transfus Apher Sci. 2021;60(5):103241.
- 459 17. Dineshkumar T, Dhanapriya J, Sakthirajan R, Thirumalvalavan K, Kurien AA, Balasubramaniyan T, et
- 460 al. Thrombotic microangiopathy due to Viperidae bite: Two case reports. Indian J Nephrol. 2017;27(2):161.
- 461 18. Erkurt MA, Kuku I, Kaya E, Ozgen U, Berber I, Koroglu M, et al. Therapeutic plasma-exchange in
- 462 hematologic disease: results from a single center in Eastern Anatolia. Transfus Apher Sci. 2013;48(3):335-9.
- 463 19. Rathnayaka RN, Ranathunga PAN, Kularatne SAM, Sugathadasa K. Therapeutic plasma exchange for
- 464 venom-induced thrombotic microangiopathy following hump-nosed pit viper (genus: Hypnale) bites: a
- 465 prospective observational study. Wilderness Environ Med. 2022;33(4):386–98.
- 466 20. Isbister GK, Little M, Cull G, McCoubrie D, Lawton P, Szabo F, et al. Thrombotic microangiopathy
- 467 from Australian brown snake (Pseudonaja) envenoming. Intern Med J. 2007 Aug;37(8):523-8.
- 468 21. Rahmani TRI, Nasasra T, Fuchs L, Almog Y, Lurie Y, Galante O. Acute thrombotic microangiopathic
- 469 kidney injury due to Echis coloratus envenomation. Clin Toxicol Phila Pa. 2020 Apr;58(4):284-6.
- 470 22. Obeidat MB, Al-Swailmeen AM, Al-Sarayreh MM, Rahahleh KM. Thrombotic microangiopathy
- 471 following Arabian saw-scaled viper (Echis coloratus) bite: Case report. Am J Case Rep. 2020;21:e922000-1.
- 472 23. Keyler DE. Envenomation by the lowland viper (Proatheris superciliaris): severe case profile
- 473 documentation. Toxicon. 2008;52(8):836-41.
- 474 24. Kornalík F, Vorlová Z. Non-specific therapy of a hemorrhagic diathesis after a bite by a young Bothrops
- 475 asper (barba amarilla): a case report. Toxicon Off J Int Soc Toxinology. 1990;28(12):1497-501.

- 476 25. Valenta J, Stach Z, Kolář M. Envenoming after a snakebite from the Northeast African saw-scaled viper
- Echis pyramidum: prolonged therapy upon failed treatment by antivenom. Prague Med Rep. 2011;112(3):226–
- 478 35.
- 479 26. Sampley S, Sakhuja V, Bhasin D, Singh K, Singh H. Plasmapheresis for pulmonary hemorrhage
- 480 following viperine snakebite: a case report with review of literature. Indian J Crit Care Med Peer-Rev Off Publ
- 481 Indian Soc Crit Care Med. 2020;24(10):986.
- 482 27. Grace M, Jacob KJ, Jayakumar, P. A. Secondary capillary leak syndrome Plasmapheresis: Is it the
- answer? | International Archives of Integrated Medicine | EBSCOhost [Internet]. Vol. 2. 2015 [cited 2024 Jun 30].
- 484 p. 187. Available from:
- https://openurl.ebsco.com/contentitem/gcd:102145212?sid=ebsco:plink:crawler&id=ebsco:gcd:102145212
- 486 28. Hameed S, Memon M, Khan S. Guillain-Barre Syndrome Following a Snakebite: A Case Report and
- 487 Review of Literature. Cureus [Internet]. [cited 2023 Oct 20];11(7):e5278. Available from:
- 488 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764639/
- 489 29. Cobcroft RG, Williams A, Cook D, Williams DJ, Masci P. Hemolytic uremic syndrome following taipan
- envenomation with response to plasmapheresis. Pathology (Phila) [Internet]. 1997 [cited 2023 Oct 20];29(4):399—
- 491 402. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0031302516349893
- 492 30. Chuang TY, Lin SW, Chan RC. Guillain-Barré syndrome: an unusual complication after snake bite. Arch
- 493 Phys Med Rehabil. 1996 Jul;77(7):729–31.
- 494 31. Withana M, Rodrigo C, Gnanathasan A, Gooneratne L. Presumptive thrombotic thrombocytopenic
- 495 purpura following a hump-nosed viper (Hypnale hypnale) bite: a case report. J Venom Anim Toxins Trop Dis.
- 496 2014;20(1):1-6.
- 497 32. Mitrakrishnan JY, Bandula CW, Mitrakrishnan CS, Somaratna K, Jeyalakshmy S. Haemolytic uremic
- 498 syndrome a hitherto unreported complication of humpnosed viper envenomation. Indian J Hematol Blood
- 499 Transfus Off J Indian Soc Hematol Blood Transfus. 2013 Jun;29(2):116–8.
- 500 33. Rathnayaka RN, Ranathunga PAN, Kularatne SA. Thrombotic microangiopathy, hemolytic uremic
- 501 syndrome, and thrombotic thrombocytopenic purpura following hump-nosed pit viper (Genus: Hypnale)
- envenoming in Sri Lanka. Wilderness Environ Med. 2019;30(1):66–78.

- 503 34. Srivastava A, Taly AB, Gupta A, Moin A, Murali T. Guillain-Barré syndrome following snake bite: An
- 504 unusual complication. Ann Indian Acad Neurol [Internet]. 2010 [cited 2023 Oct 20];13(1):67–8. Available from:
- 505 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859593/
- 506 35. Reddy SP, Phadnis SA, Kumari P, Sharma N, Sethi J, Pannu AK, et al. Thrombotic microangiopathy in
- 507 Russel's viper envenomation. QJM Int J Med. 2022;115(7):486-7.
- 508 36. Cañas CA, Vecino MJ, Posso-Osorio I. Atypical Hemolytic Uremic Syndrome in a Patient With
- Bothrops asper Envenomation. Wilderness Environ Med [Internet]. 2022 Mar 1 [cited 2023 Jul 28];33(1):109-509
- 510 15. Available from: https://www.sciencedirect.com/science/article/pii/S108060322100168X
- 511 37. Namal Rathnayaka RMMK, Nishanthi Ranathunga PEA, Kularatne SAM. Thrombotic Microangiopathy
- 512 Following Hypnale zara (Hump-Nosed Pit Viper) Envenoming: The First Known Case Report from Sri Lanka.
- 513 Wilderness Environ Med [Internet]. 2020 Mar 1 [cited 2023 Jul 28];31(1):71-7. Available from:
- 514 https://www.sciencedirect.com/science/article/pii/S1080603219301619
- 515 38. GodavarI KSV. Hemolytic Uremic Syndrome-An unusual complication of snake envenomation. Univ J
- 516 Med Med Spec. 2016;2(2).
- 517 39. Murthy PR, Ak AK, Karanth S, Kalashetty M. Thrombotic thrombocytopenic purpura in a patient with
- snake bite. Indian J Case Rep [Internet]. 2019 Jun 28 [cited 2024 Jun 30];5(3):277-9. Available from: 518
- 519 https://mansapublishers.com/index.php/ijcr/article/view/1615
- 520 40. Wijewickrama ES, Gooneratne LV, Gnanathasan A, Gawarammana I, Gunatilake M, Isbister GK.
- 521 Thrombotic microangiopathy and acute kidney injury following Sri Lankan Daboia russelii and Hypnale species
- envenoming. Clin Toxicol Phila Pa. 2020 Oct;58(10):997-1003. 522
- 523 41. Janarthanam MJ. Interesting case of AIDP following snake bite. Univ J Med Med Spec. 2016;2(5).
- 524 42. Senthilkumaran S, Miller SW, Williams HF, Thirumalaikolundusubramanian P, Vaiyapuri S, Patel K.
- 525 Hirata's disease (insulin autoimmune syndrome) following envenomation by a common krait. Toxicon Off J Int
- 526 Soc Toxinology. 2022 Nov;219:106923.
- 527 43. Priyankara S, Rathnasiri V, Mihiran T, Premawansa G, Isbister GK, Silva A. Mild venom-induced
- 528 consumption coagulopathy associated with thrombotic microangiopathy following a juvenile Russell's viper
- 529 (Daboia russelii) envenoming: A case report. Toxicon Off J Int Soc Toxinology. 2022 Jun;212:8-10.

- 530 44. Laothong C, Sitprija V. Decreased parasympathetic activities in Malayan krait (Bungarus candidus)
- envenoming. Toxicon Off J Int Soc Toxinology. 2001 Sep;39(9):1353–7.
- 532 45. Herath N, Wazil A, Kularatne S, Ratnatunga N, Weerakoon K, Badurdeen S, et al. Thrombotic
- 533 microangiopathy and acute kidney injury in hump-nosed viper (Hypnale species) envenoming: A descriptive study
- 534 in Sri Lanka. Toxicon [Internet]. 2012 Jul 1 [cited 2023 Jul 28];60(1):61-5. Available from:
- 535 https://www.sciencedirect.com/science/article/pii/S0041010112000876
- 536 46. Bava D, Kumar PHA, Gupta A, Mandal S, Bajpayee A, Gopalakrishnan M, et al. Redefining the role of
- 537 therapeutic plasma exchange in complications of Echis carinatus sochureki envenomation refractory to anti-snake
- 538 venom: A case series. Asian J Transfus Sci. 2023;17(2):295–300.
- 539 47. Elmoqaddem A, Mrani Alaoui N, Cherrad. M. Hmidi T, Choumi F, Nadour K. Plasma Exchange in a
- Patient with a Severe Viper Bite. Saudi J Med Pharm Sci [Internet]. 2021 Jan 16 [cited 2024 Jun 30];7(1):50–1.
- Available from: https://saudijournals.com/media/articles/SJMPS 71 50-51.pdf
- 542 48. Casamento AJ, Isbister GK. Thrombotic microangiopathy in two tiger snake envenomations. Anaesth
- 543 Intensive Care. 2011;39(6):1124–7.
- 544 49. Chugh KS. Snake-bite-induced acute renal failure in India. Kidney Int. 1989 Mar;35(3):891–907.
- 545 50. Bull BS, Rubenberg ML, Dacie JV, Brain MC. Microangiopathic haemolytic anaemia: mechanisms of
- red-cell fragmentation: in vitro studies. Br J Haematol. 1968 Jun;14(6):643–52.
- 547 51. Malaque CMS, Duayer IF, Santoro ML. Acute kidney injury induced by thrombotic microangiopathy in
- two cases of Bothrops envenomation. Clin Toxicol. 2019;57(3):213–6.
- 549 52. Bucaretchi F, Pimenta MMB, Borrasca-Fernandes CF, Prado CC, Capitani EMD, Hyslop S. Thrombotic
- 550 microangiopathy following Bothrops jararaca snakebite: case report. Clin Toxicol. 2019;57(4):294–9.
- 551 53. Okuda D, Nozaki C, Sekiya F, Morita T. Comparative Biochemistry of Disintegrins Isolated from Snake
- Venom: Consideration of the Taxonomy and Geographical Distribution of Snakes in the Genus Echis1. J Biochem
- 553 (Tokyo) [Internet]. 2001 Apr 1 [cited 2023 Oct 20];129(4):615–20. Available from:
- https://doi.org/10.1093/oxfordjournals.jbchem.a002898

- 555 54. Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles
- and capillaries: an undescribed disease. Arch Intern Med [Internet]. 1925 Jul 1 [cited 2023 Oct 20];36(1):89–93.
- 557 Available from: https://doi.org/10.1001/archinte.1925.00120130092009
- 558 55. Clark WF. Thrombotic Microangiopathy: Current Knowledge and Outcomes With Plasma Exchange.
- 559 Semin Dial [Internet]. 2012 Mar [cited 2023 Oct 20];25(2):214–9. Available from:
- 560 https://onlinelibrary.wiley.com/doi/10.1111/j.1525-139X.2011.01035.x
- 56. Neil J, Choumet V, Le Coupanec A, d'Alayer J, Demeret S, Musset L. Guillain-Barre syndrome: first
- description of a snake envenomation aetiology. J Neuroimmunol. 2012 Jan 18;242(1–2):72–7.
- 563 57. Aneja: Idiopathic systemic capillary leak syndrome Google Scholar [Internet]. [cited 2024 Jun 30].
- 564 Available from:
- https://scholar.google.com/scholar\_lookup?journal=UpToDate&title=Idiopathic+systemic+capillary+leak+synd
- rome&author=R+Aneja&author=S+Manaker&author=G+Finlay&
- 567 58. Udayabhaskaran V, Arun Thomas ET, Shaji B. Capillary Leak Syndrome Following Snakebite
- 568 Envenomation. Indian J Crit Care Med [Internet]. 2017 Oct;21(10):698-702. Available from: https://search-
- 569 ebscohost-
- 570 com.elibraryaiimsrishikesh.remotexs.in/login.aspx?direct=true&db=ccm&AN=125851540&site=ehost-live
- 571 59. Adamski J. Thrombotic microangiopathy and indications for therapeutic plasma exchange. Hematology
- 572 [Internet]. 2014 Dec 5 [cited 2023 Oct 20];2014(1):444–9. Available from:
- 573 https://ashpublications.org/hematology/article/2014/1/444/20443/Thrombotic-microangiopathy-and-indications-
- 574 for
- 575 60. Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, et al. Guidelines on
- the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of
- 577 the American Society for Apheresis: The Seventh Special Issue. J Clin Apheresis. 2016 Jun;31(3):149–62.
- 578 61. Kaplan AA. Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis Off J Natl Kidney
- 579 Found. 2008 Dec;52(6):1180–96.
- 580 62. Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J
- 581 Kidney Dis Off J Natl Kidney Found. 1994 Jun;23(6):817–27.

583

584

585

586

587

588

589

Page **30** of **30** 

63. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, et al. Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apheresis. 2010;25(3):83–177.